Fiscal Q2 (March 31) C$ 6M in sales (C$ 5.8M in Q1) with 78% Gross Margins. About C$ 0.5M in Net Income due to high marketing costs as company is looking to expand on Saudi Arabia success.
Pretty much at a run rate of $C 24M in annualized revenue vs. a $C 42M basic market cap so >2X P/Sales with 70-80% Gross Margins, 250% YoY revenue growth, and no debt.
Only another 2M options/warrants oustanding on basic common shares of 19.3M so fully diluted market cap will not blow-out.
Direction appears up but there is huge single-customer risk here. Per the FS Notes for Q2 C$ 5.3M of C$ 6.0M in revenue came from 'international customers' and I believe this is the Saudi Arabian health ministry. This is what is holding Covalon down of course.
Conference call tomorrow I may dial into and ask to confirm this.
If they can show growth later this year to non-Saudi customers direction here is up.
I did some looking and Covalon guided for C$ 11M MINIMUM in sales from Saudi Arabia in F2017 so new C$ 24M revenue run-rate either means Saudi sales are overdelivering year-to-date or they have new non-Saudi customers which would pull the share price upwards IMO.
The fiscal 2016 (before Saudi sales started) segmented disclosure note states that they did C$ 4M in sales internationally for the 12 months ended September 30, 2016.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.